Today: 30 June 2026
Browse Category

NYSE:MRK 7 February 2026 - 15 June 2026

Amazon Shares Slip After $17.5 Billion AI Loan Draws Focus to AMZN Cash Flow

Amazon takes number one spot on 2026 Fortune 500; regional shifts seen

Amazon has taken the No. 1 spot on the 2026 Fortune 500, Fortune said, unseating Walmart after 13 years at the top. The change put Amazon ahead for the first time in more than a decade and drove shifts in regional tallies for Pennsylvania, New Jersey and New England. Fortune’s 72nd annual list put the collective revenue at $21.0 trillion, with profits at $2.1 trillion and a workforce of 30.5 million worldwide. Erie Insurance traded higher. The insurer out of Pennsylvania moved up 15 spots to No. 308 on the 2026 Fortune 500, now with 23 straight years on the list. Fortune listed Erie Insurance at $14.62 billion in revenue and $1.13 billion in profit. The company said its current streak on the Fortune 500 goes back to 2003.
15 June 2026
···········
Dow Drops After Hours, AI Rally Sidesteps Blue Chips

Dow Drops After Hours, AI Rally Sidesteps Blue Chips

Dow slips as S&P 500, Nasdaq recover on tech bounce The Dow Jones Industrial Average lost ground Monday, dipping 104.70 points, or 0.21%, to settle at 50,762.08. The index caught a range between 50,761.97 and 51,277.15. The S&P 500 and Nasdaq pushed higher as buyers moved back into tech and chip stocks after Friday’s selloff. Split trading drew focus as investors wondered if Friday’s drop would prove to be just a blip or the beginning of a steeper slide. The Dow covers 30 major U.S. blue chips and uses a price-weighted system, so pricier stocks have greater sway than firms with a larger market cap.
8 June 2026
·····
Merck Stock Gains as Keytruda Concerns Ease, Investors Look to Pipeline Bets

Merck Stock Gains as Keytruda Concerns Ease, Investors Look to Pipeline Bets

Merck & Co. shares climbed 4.9% to $120.26 late Thursday, adding $5.59 and putting the drugmaker among the top movers in a Dow rally paced by healthcare stocks. UnitedHealth and Merck made up about a third of the Dow’s gains earlier in the day, MarketWatch said. Merck is still defined by how quickly it can find a follow-up to Keytruda. The blockbuster cancer drug brought in over $30 billion in 2025, nearly half of Merck’s sales. U.S. exclusivity for Keytruda runs out in 2028, when generics could hit.
4 June 2026
··
Dow Jones Falls as Bond Yields Signal Trouble for Bulls

Dow Jones Closes at Record as Oil Sinks; AI Stocks Pause

The Dow Jones Industrial Average closed at a record high on Wednesday, rising 189.08 points, or 0.37%, to 50,650.76, as investors bought healthcare and consumer shares while the AI-led rally cooled. The S&P 500 edged up 0.02% and the Nasdaq Composite added 0.08%, leaving the broader market nearly flat after a run of record-setting gains. The split mattered because it showed money moving outside the biggest technology winners. The Dow is a price-weighted gauge of 30 U.S. blue-chip companies, meaning stocks with higher share prices carry more influence than companies with larger market value; on Wednesday, that structure helped the index benefit from gains in steadier consumer and healthcare names.
27 May 2026
···············
Terns Pharmaceuticals stock stops trading as Merck’s $53 cash deal takes over the chart

Terns Pharmaceuticals stock stops trading as Merck’s $53 cash deal takes over the chart

Terns Pharmaceuticals shares aren’t budging—not surprising, since the merger is done and Nasdaq trading is finished. The last quote for the stock came in at $52.95, just shy of Merck’s $53-per-share cash deal. With Terns now fully absorbed into Merck, its common stock has dropped off the Nasdaq Global Select Market and won’t trade again. This explains the chart’s flatline—no real movement left. When a cash buyout is nearly a done deal, the shares just shadow the expected payout, with barely any margin for risk or timing. In this case, almost no spread remained after Merck wrapped up its tender offer, leaving leftover shares automatically converted to $53 cash per share.
12 May 2026
····
Dow Jones Today: Why the Blue-Chip Rally Stalled as Apple, S&P 500 and Nasdaq Pushed Higher

Dow Jones Today: Why the Blue-Chip Rally Stalled as Apple, S&P 500 and Nasdaq Pushed Higher

The Dow Jones Industrial Average lost steam Friday, pulling back from an early run at 50,000. By 12:34 p.m. in New York, the index slipped 78.72 points, or 0.16%, to 49,573.42. It started the day at 49,832.57 and briefly hit 49,988.56, but tariff worries weighed on Apple and other recent earnings gainers, trimming the rally. This shift stands out as the Dow lags behind, failing to keep up with the tech-fueled rally boosting the rest of the market. Both the S&P 500 and Nasdaq Composite climbed to all-time highs. Analysts polled by LSEG now see S&P 500 earnings up 27.8% in the first quarter—the sharpest growth since late 2021.
1 May 2026
·····
SCHD ETF Rebalance Adds Abbott, UnitedHealth as Dividend Fund Inflows Hit 4-Year High

SCHD ETF Rebalance Adds Abbott, UnitedHealth as Dividend Fund Inflows Hit 4-Year High

NEW YORK, March 30, 2026, 4:56 PM EDT Schwab U.S. Dividend Equity ETF, with $83.9 billion in assets, pushed further into health care during its annual portfolio shake-up. Abbott Laboratories and UnitedHealth Group are now among its largest holdings, as cash continues to pour into dividend-focused funds.
30 March 2026
············
Terns Pharmaceuticals (TERN) Stock Holds Near Merck’s $53 Offer After $6.7 Billion Buyout

Terns Pharmaceuticals (TERN) Stock Holds Near Merck’s $53 Offer After $6.7 Billion Buyout

In U.S. premarket action Thursday, Terns Pharmaceuticals was pegged at $52.86, matching Wednesday’s close and sitting roughly 14 cents under Merck’s $6.7 billion all-cash bid for the biotech. Terns had surged 5.8% by the end of Wednesday’s session. The slim spread signals that investors are betting the deal will likely go through as planned. This is not just about Terns—Merck is under pressure to diversify, aiming to soften its reliance on Keytruda ahead of the drug’s looming U.S. exclusivity loss in 2028.
26 March 2026
···
Merck to Buy Terns Pharmaceuticals for $6.7 Billion to Boost Cancer Pipeline as Keytruda Patent Expiry Nears

Merck to Buy Terns Pharmaceuticals for $6.7 Billion to Boost Cancer Pipeline as Keytruda Patent Expiry Nears

Merck is set to acquire Terns Pharmaceuticals in a $6.7 billion cash deal, offering $53 per share, the companies said Wednesday. The move hands Merck an experimental leukemia drug and underlines its push into oncology. The announcement followed a Financial Times report earlier in the day that discussions were already advanced. Timing is crucial here. Merck’s blockbuster cancer drug Keytruda faces some patent expirations in 2028. In 2025, Keytruda pulled in over $30 billion—almost half of Merck’s total revenue—so investors are watching closely for signs of what comes next. The company is racing to lock down fresh sources of growth.
25 March 2026
··
Merck stock pops on Deutsche Bank upgrade — what to watch ahead of ASCO GU

Merck stock pops on Deutsche Bank upgrade — what to watch ahead of ASCO GU

New York, Feb 13, 2026, 16:43 EST — After-hours Merck & Co climbed 1.8% to $121.41 in Friday’s after-hours session, boosted by a Deutsche Bank upgrade to buy and a raised price target. Analyst James Shin argued, “We believe the market is currently undervaluing MRK … a clear path for MRK to navigate this transition.” Deutsche Bank projects that between the pipeline and recent acquisitions, Merck could tack on over $35 billion in risk-adjusted revenue by 2035.
13 February 2026
··
Merck stock is inches from a 52-week high — and an insider just sold shares

Merck stock is inches from a 52-week high — and an insider just sold shares

New York, Feb 8, 2026, 13:04 EST — The market has closed. Merck & Co, Inc. finished Friday’s session up 1.82% at $121.93, putting the stock less than half a percent under its 52-week high as U.S. equities broadly rallied. While Pfizer and Eli Lilly posted bigger moves, Merck outperformed Johnson & Johnson. Trading volume landed at roughly 13 million shares, trailing the 50-day average, MarketWatch data shows.
8 February 2026
··
1 2 3 … 8

Stock Market Today

  • Inflation Fears Look Overdone, Fed Chief Warsh Tones Down Hawkish Talk
    June 30, 2026, 9:52 AM EDT. Inflation worries seem bigger than the data shows, with price gains coming in softer than many think. Federal Reserve Chair Kevin Warsh, usually known for tough talk on rates, took a softer line. Some analysts say markets have read too much into the outlook for rate hikes, which could keep the stock market steady. Investors are working through mixed economic messages.
Go toTop